Pay in 4 interest-free payments of $21.25 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
Krajka-Kuźniak V
is a potent and selective inhibitor of the hedgehog signaling with an IC50 ~46 nM
Combined Chemical Treatment Enables Oct4-Induced Reprogramming from Mouse Embryonic Fibroblasts
Constitutive activation of Hh pathway signaling has been observed in various types of malignancies
PubMed PMID: 18378004
Ipragliflozin 98 phosphate Krajka-Kuźniak VIpragliflozin, also known as ASP1941, is a potent and selective SGLT2 inhibitor for treatment of type 2 diabetes. Ipragliflozin treatment improved glycaemic control when added to metformin therapy and may be associated with weight loss and reductions in blood pressure compared to placebo. Ipragliflozin improves not only hyperglycemia but also diabetes obesity associated metabolic abnormalities in type 2 diabetic mice. It was approved for use in Japan
US$ 500.00
US$ 500.00
US$ 500.00
US$ 500.00